🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University13 Changhai Hospital9 Ruijin Hospital7 Akeso3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine3
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Trials with a site in Shanghai

53 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
NCT07806058Pancreatic Cancer
DrugsHRS-7172·HRS-4642·Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
140
Shanghai
2026-09
Not yet open
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
NCT07784374Pancreatic Cancer
DrugsGFS202A·GFH276·Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 2
120
Shanghai
2026-08-31
Recruiting
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
NCT07707531Gastric Cancer, Pancreatic Cancer
Huashan Hospital
Phase EARLY_PHASE1
10
Shanghai
2026-06-01
Recruiting
Multicentric Database for KRAS Mutant Pancreatic Cancer
NCT07557849Pancreatic Cancer
Fudan University
Observational
1,000
Shanghai
2026-05-22
Recruiting
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
NCT07649928Pancreatic Cancer
Ruijin Hospital
Phase EARLY_PHASE1
24
Shanghai
2026-05-18
Not yet open
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
NCT07014878Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Beijing DCTY Biotech Co.,Ltd.
Phase 1
18
Shanghai
2026-05
Not yet open
Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
NCT07554742Pancreatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Ruijin Hospital
Observational
64
Shanghai
2026-04-15
Recruiting
AI-Powered Precision Decision-Making for Pancreatic Diseases
NCT07439757Pancreatic Cancer, Diagnose Disease, IPMN, Pancreatic, Pancreatic Cystic Lesions
Changhai Hospital
Observational
2,000
Shanghai
2026-03-01
Not yet open
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
NCT07383922Pancreatic Cancer
DrugsFG-M108·Nab-paclitaxel·Gemcitabine
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
524
Shanghai
2026-02-28
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsLevofolinate·Setidegrasib·Liposomal Irinotecan·5-FU
Astellas Pharma Global Development, Inc.
Phase 3
614
Shanghai
2026-02-17
Recruiting
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
NCT07425483Pancreatic Cancer
Changhai Hospital
Phase 1
9
Shanghai
2026-02-12
Not yet open
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
NCT07272109Pancreatic Cancer
DrugsNab-paclitaxel·Gemcitabine
Fudan University
Phase 3
210
Shanghai
2026-01-01
Recruiting
A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
NCT07561814Pancreatic Cancer
Shanghai Zhongshan Hospital
Observational
1,030
Shanghai
2025-12-09
Recruiting
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
NCT07229768Pancreatic Cancer
Yan Xing
Phase EARLY_PHASE1
4
Shanghai
2025-10-15
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
NCT07114315Pancreatic Cancer
DrugsAK130·Ivonescimab
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT07131514Pancreatic Cancer
DrugsHRS-4642·Adebrelimab
Ruijin Hospital
Phase 2
30
Shanghai
2025-08-25
Recruiting
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT07117045Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
Changhai Hospital
Observational
400,000
Shanghai, Jiaxing, Ningbo
2025-08-15
Recruiting
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
NCT07066098Pancreatic Cancer
DrugIBI343
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
201
Shanghai
2025-08-04
Recruiting
PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.
NCT07167264Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
200
Shanghai
2025-07-16
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
NCT06938282Pancreatic Cancer
DrugHRS-4642
Shanghai Zhongshan Hospital
Phase 2
60
Shanghai
2025-06-23
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
NCT06816823Pancreatic Cancer
Changhai Hospital
Phase 1
30
Shanghai
2025-04-07
Recruiting
The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
NCT07015580Oral Microbiota, Pancreatitis, Pancreatic Cancer
Ruijin Hospital
Observational
360
Shanghai
2025-02-18
Recruiting
A Study of GC203 TIL in PDCA (RJ)
NCT06828328Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
10
Shanghai
2025-02-10
Recruiting
Pancreatic Cancer and Diabetes Mellitus
NCT06585072Pancreatic Cancer, Surgery, Diabetes Mellitus
Shanghai Changzheng Hospital
Observational
150
Shanghai
2025-01-03
Recruiting
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT06587061Pancreatic Cancer
DrugHRS-4642
Ruijin Hospital
Phase 2
30
Shanghai
2024-12-03
Recruiting
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
NCT06601283Pancreatic Cancer
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Recruiting
Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
NCT06598033Pancreatic Cancer
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Not yet open
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
NCT06621095Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer
DrugsBenmelstobart·Anlotinib·Nab-paclitaxel·Gemcitabine
RenJi Hospital
Phase 2
104
Shanghai
2024-10-30
Recruiting
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
NCT06547736Pancreatic Cancer
DrugsSHR-A1904·HRS-4642·SHR-A2102·Trastuzumab Rezetecan
Fudan University
Phase 2
160
Shanghai
2024-10-14
Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010Pancreatic Cancer
Ruijin Hospital
Observational
30
Shanghai
2024-09-24
Recruiting
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
NCT06427447Pancreatic Cancer
Changhai Hospital
Phase 3
770
Shanghai
2024-08-06
Recruiting
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
NCT06638866Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
Changhai Hospital
Observational
5,000
Shanghai, Jiaxing, Ningbo
2024-08-03
Recruiting
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
NCT06541340Pancreatic Cancer, Obstructive Jaundice
Ruijin Hospital
Not applicable
360
Shanghai
2024-08-01
Active, closed
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
NCT06313970Pancreatic Cancer
DrugsIparomlimab and Tuvonralimab·Nab-paclitaxel·Gemcitabine·Bevacizumab
Fudan University
Phase 2
58
Shanghai
2024-06-20
Recruiting
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
NCT06427239Pancreatic Cancer
DrugsHRS-4642·SHR-8068·Adebrelimab·Bevacizumab
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Recruiting
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
NCT06427460Pancreatic Cancer
Changhai Hospital
Phase 2
67
Shanghai
2024-05-12
Not yet open
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06370754Pancreatic Cancer
DrugsJS015·JS007·JS004·Irinotecan liposome
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
DrugIrinotecan liposome II combination therapy
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
NCT06249321Pancreatic Cancer, Radiotherapy
DrugsIMRT·MFOLFIRINOX
Fudan University
Phase 2
30
Shanghai
2024-04-01
Recruiting
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
NCT06196788Pancreatic Cancer
DrugsNab-paclitaxel·Gemcitabine
Fudan University
Phase 2
30
Shanghai
2024-03-01
Not yet open
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
NCT06217042Pancreatic Cancer
DrugsHR070803·5Fluorouracil·Calcium folinate·Capecitabine
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
Bile Omics for Diagnosing Indeterminate Biliary Strictures
NCT07007832Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
260
Shanghai
2024-01-01
Not yet open
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
NCT06156267Pancreatic Cancer
DrugAdebrelimab
Fudan University
Phase EARLY_PHASE1
30
Shanghai
2024-01
Recruiting
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147Pancreatic Cancer
Fudan University
Observational
276
Shanghai
2023-12-18
Recruiting
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
NCT06307080Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2023-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
DrugCT041 autologous CAR T-cell
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05827796Pancreatic Cancer
DrugsKN046·IN10018·Albumin-Bound Paclitaxel·Gemcitabine
InxMed (Shanghai) Co., Ltd.
Phase 1/2
70
Shanghai
2022-12-08
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
DrugsFludarabine·Cyclophosphamide
Changhai Hospital
Phase 1/2
30
Shanghai
2021-10-21
Recruiting
Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
NCT04743479Pancreatic Cancer, Diabetes, Familial Pancreatic Cancer, Pancreatic Cystic Neoplasm
Changhai Hospital
Observational
5,000
Shanghai
2020-12-01
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

42 of the 53 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 53 studies
PhaseStudiesRecruitingShare
Observational131224.5%
Phase 212922.6%
Phase 38515.1%
Phase 1549.4%
Phase 1/2539.4%
Phase EARLY_PHASE1549.4%
Not applicable335.7%
Phase 2/3223.8%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Fudan University138
Changhai Hospital99
Ruijin Hospital76
Akeso33
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine33
Shanghai Zhongshan Hospital22
Astellas Pharma Global Development, Inc.11
Beijing DCTY Biotech Co.,Ltd.10
CARsgen Therapeutics Co., Ltd.11
Evopoint Biosciences Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.